Inhibrx, Inc. (INBX)
NASDAQ: INBX · IEX Real-Time Price · USD
13.56
-0.18 (-1.31%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Inhibrx Revenue
In the year 2023, Inhibrx had annual revenue of $1.63M with 24.26% growth.
Revenue (ttm)
$1.63M
Revenue Growth
+24.26%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
172
Market Cap
196.29M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.63M | 319.00K | 24.26% |
Dec 31, 2022 | 1.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionINBX News
- 27 days ago - Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX) - Benzinga
- 5 weeks ago - Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi - PRNewsWire
- 7 weeks ago - Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off - PRNewsWire
- 7 weeks ago - INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX - Business Wire
- 7 weeks ago - Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger - PRNewsWire
- 4 months ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results - PRNewsWire
- 5 months ago - Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi - PRNewsWire
- 5 months ago - Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline - Investopedia